EMMA MONIQUE TILLMAN, Pharm.D.

Assistant Professor
Dept of Clinical Pharmacy

Office: Lab 321 Le Bonheur Research Center
Tel: (901) 287-5349
etillman@uthsc.edu

Education

  • Other, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN, Pediatric Nutrition and Metabolic Support Fellowship
  • Other, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN, Pediatric Pharmacotherapy Residency
  • Pharm.D., Bulter University, Indianapolis, IN, Pharmacy
  • B.A., Ball State University, Muncie, IN, Music Performance

Research Description

Dr. Tillman’s research is focused on the treatment of parenteral nutrition (PN)-associated liver disease (PNALD) with omega-3 long chain polyunsaturated fatty acids (ω3PUFA). PNALD occurs in children maintained on long-term PN. The multi-factorial etiology of PNALD is not well understood; therefore, prevention and treatment present a challenge. Recent evidence has suggested that ω3PUFA may be effective for the treatment and/or prevention of PNALD, although the mechanism has not been defined. Dr. Tillman has developed a translational research program including a pilot clinical trial evaluating potential early markers of PNALD and treatment with ω3PUFA, and this clinical study is complimented with cell culture experiments aimed to evaluate cellular pathways that are affected by ω3PUFA in a PNALD model. Results of this research will not only provide a better understanding of PNALD, but also increase understanding of cellular pathways affected by ω3PUFA. This could then potentially be applied to other diseases where ω3PUFA have shown benefit.

Research Keywords

liver disease, cholestasis, omega-3 long chain polyunsaturated fatty acids, apoptosis

Research Interest/Specialty

Emma Tillman is a Research Assistant Professor in the Department of Clinical Pharmacy at the University of Tennessee Health Science Center and a clinical pharmacist in the area of pediatric nutrition and metabolic support at Le Bonheur Children’s Hospital. Dr. Tillman’s research is focused on the treatment of parenteral nutrition (PN)-associated liver disease (PNALD) with omega-3 long chain polyunsaturated fatty acids (ω3PUFA).

Publications

  1. Stultz, JS, Tillman, EM, Helms, RA. Plasma citrulline concentration as a biomarker for bowel loss and adaptation in hospitalized pediatric patients requiring parenteral nutrition. Nutr Clin Pract, 26 (6), 681-7, 2011.
  2. Tillman, EM, Helms, RA, Black, DD. Eicosapentaenoic Acid and Docosahexaenoic Acid Synergistically Attenuate Bile Acid-Induced Hepatocellular Apoptosis. JPEN J Parenter Enteral Nutr, 2011.
  3. Barone, JV, Tillman, EM, Ferry, RJ. Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate. J Pediatr Pharmacol Ther, 16 (4), 291-7, 2011.
  4. Tillman, EM, Crill, CM, Black, DD, Hak, EB, Lazar, LF, Christensen, ML, Huang, EY, Helms, RA. Enteral fish oil for treatment of parenteral nutrition-associated liver disease in six infants with short-bowel syndrome. Pharmacotherapy, 31 (5), 503-9, 2011.
  5. Tillman, EM, Helms, RA. Omega-3 long chain polyunsaturated Fatty acids for treatment of parenteral nutrition-associated liver disease: a review of the literature. J Pediatr Pharmacol Ther, 16 (1), 31-8, 2011.
  6. Tillman, EM, Storm, MC, Hill, DM, Helms, RA. In vitro stability of polyurethane and silicone feeding tubes exposed to fish oil. Am J Health Syst Pharm, 67 (23), 1986-8, 2010.